Nickolas Tsakmaklis

765 total citations
34 papers, 363 citations indexed

About

Nickolas Tsakmaklis is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Nickolas Tsakmaklis has authored 34 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Genetics, 8 papers in Immunology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Nickolas Tsakmaklis's work include Chronic Lymphocytic Leukemia Research (32 papers), Lymphoma Diagnosis and Treatment (6 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Nickolas Tsakmaklis is often cited by papers focused on Chronic Lymphocytic Leukemia Research (32 papers), Lymphoma Diagnosis and Treatment (6 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Nickolas Tsakmaklis collaborates with scholars based in United States, China and Spain. Nickolas Tsakmaklis's co-authors include Zachary R. Hunter, Steven P. Treon, Jorge J. Castillo, Guang Yang, Lian Xu, Yang Cao, Sandra Kanan, Christopher J. Patterson, Xingguang Liu and Scott J. Rodig and has published in prestigious journals such as Blood, British Journal of Haematology and Leukemia.

In The Last Decade

Nickolas Tsakmaklis

22 papers receiving 358 citations

Peers

Countries citing papers authored by Nickolas Tsakmaklis

Since Specialization

Citations

This map shows the geographic impact of Nickolas Tsakmaklis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nickolas Tsakmaklis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nickolas Tsakmaklis more than expected).

Fields of papers citing papers by Nickolas Tsakmaklis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nickolas Tsakmaklis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nickolas Tsakmaklis. The network helps show where Nickolas Tsakmaklis may publish in the future.

Co-authorship network of co-authors of Nickolas Tsakmaklis

This figure shows the co-authorship network connecting the top 25 collaborators of Nickolas Tsakmaklis. A scholar is included among the top collaborators of Nickolas Tsakmaklis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nickolas Tsakmaklis. Nickolas Tsakmaklis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications 2025 ·Blood ·(unknown), Nickolas Tsakmaklis, (unknown), (unknown), (unknown), (unknown), Maria Luisa Guerrera, Gottfried von Keudell, Andrew R. Branagan, Zachary R. Hunter, (unknown), Shayna Sarosiek, Jorge J. Castillo	0
2	High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study 2025 ·Blood ·Jorge J. Castillo, Gottfried von Keudell, Andrew R. Branagan, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kirsten Meid, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, (unknown), Nickolas Tsakmaklis, Christopher J. Patterson, Zachary R. Hunter, Steven P. Treon, Shayna Sarosiek	0
3	Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas. 2025 ·Blood ·Shirong Liu, Xia Liu, Amanda Kofides, John M. Hatcher, Nickolas Tsakmaklis, (unknown), (unknown), (unknown), Jinhua Wang, Maria Luisa Guerrera, Christopher J. Patterson, Zachary R. Hunter, Shayna Sarosiek, Jorge J. Castillo, Sara J. Buhrlage, (unknown)	0
4	Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia. 2025 ·Blood ·Nickolas Tsakmaklis, (unknown), (unknown), Amanda Kofides, (unknown), Xia Liu, Hao Sun, Maria Luisa Guerrera, Christopher Patterson, Andrew R. Branagan, Shayna Sarosiek, Jorge J. Castillo, Zachary R. Hunter, (unknown)	0
5	Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom's Macroglobulinemia Undergoing Ibrutinib Monotherapy 2024 ·Blood ·Hao Sun, Romanos Sklavenitis‐Pistofidis, Xia Liu, Nickolas Tsakmaklis, Maria Luisa Guerrera, Amanda Kofides, Ana M. Gamero, Catherine Flynn, Christopher J. Patterson, Mu Hao, Lugui Qiu, Shayna Sarosiek, Jorge J. Castillo, Zachary R. Hunter, Shirong Liu, Steven P. Treon	0
6	A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis 2024 ·Blood ·Jorge J. Castillo, Shayna Sarosiek, Andrew R. Branagan, Gottfried von Keudell, Catherine Flynn, (unknown), (unknown), Kirsten Meid, (unknown), Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, (unknown), Nickolas Tsakmaklis, Christopher J. Patterson, Zachary R. Hunter, Steven P. Treon	5
7	Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia 2024 ·Blood ·Jorge J. Castillo, Shayna Sarosiek, Andrew R. Branagan, Gottfried von Keudell, Catherine Flynn, (unknown), (unknown), (unknown), Kirsten Meid, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, (unknown), Nickolas Tsakmaklis, Christopher J. Patterson, Zachary R. Hunter, Steven P. Treon	1
8	ERK1/2 pro‐survival signalling is suppressed by pirtobrutinib in ibrutinib‐resistant MYD88‐mutated lymphoma cells 2024 ·British Journal of Haematology ·Manit Munshi, Xia Liu, Amanda Kofides, Nickolas Tsakmaklis, Zachary R. Hunter, Maria Luisa Guerrera, (unknown), Joshua Gustine, Shirong Liu, John M. Hatcher, Jie Chen, Kirsten Meid, Shayna Sarosiek, Catherine Flynn, Andrew R. Branagan, (unknown), Lia Palomba, Jorge J. Castillo, Guang Yang, Steven P. Treon	0
9	Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom's Macroglobulinemia (WM) 2024 ·Blood ·Zachary R. Hunter, Ana M. Gamero, Maria Luisa Guerrera, Nickolas Tsakmaklis, Amanda Kofides, Xia Liu, Shirong Liu, (unknown), Haoyang Sun, Catherine Flynn, Kirsten Meid, (unknown), Christopher J. Patterson, Shayna Sarosiek, Jorge J. Castillo, Steven P. Treon	1
10	Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth 2023 ·Blood ·Maria Luisa Guerrera, Zachary R. Hunter, (unknown), Nickolas Tsakmaklis, Amanda Kofides, Shirong Liu, Christopher J. Patterson, Eugenio Morelli, Jorge J. Castillo, Shayna Sarosiek, Catherine Flynn, Kirsten Meid, Andrew R. Branagan, Ruben D. Carrasco, Kenneth C. Anderson, Nikhil C. Munshi, Steven P. Treon, Xia Liu	1
11	Pacritinib Blocks Key Pro-Survival Signaling Related to Mutated MYD88, Produces High Levels of Apoptosis and Overcomes Mutated BTK Cys481 Related BTK-Inhibitor Resistance 2023 ·Blood ·Shirong Liu, Amanda Kofides, Xia Liu, (unknown), Nickolas Tsakmaklis, Maria Luisa Guerrera, Christopher J. Patterson, Zachary R. Hunter, (unknown), Catherine Flynn, Kirsten Meid, (unknown), (unknown), Timothy P. White, Shayna Sarosiek, Jorge J. Castillo, Steven P. Treon	0
12	Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations 2021 ·Blood ·Manit Munshi, Xia Liu, Amanda Kofides, Nickolas Tsakmaklis, Joshua Gustine, Shayna Sarosiek, Catherine Flynn, Kirsten Meid, Timothy P. White, (unknown), Christopher J. Patterson, Andrew R. Branagan, Prafulla C. Gokhale, Michael J. Poitras, Zachary R. Hunter, Maria Luisa Guerrera, Jorge J. Castillo, Guang Yang, Steven P. Treon	7
13	Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas 2020 ·Blood Advances ·Xia Liu, (unknown), Manit Munshi, Zachary R. Hunter, Lian Xu, Amanda Kofides, Nickolas Tsakmaklis, Maria Demos, Maria Luisa Guerrera, Gloria Chan, Cristina Jiménez, Christopher J. Patterson, Kirsten Meid, Andrew Keezer, Jorge J. Castillo, Steven P. Treon, Guang Yang	15
14	CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Joshua Gustine, Lian Xu, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, (unknown), Xia Liu, Manit Munshi, Maria Luisa Guerrera, Gloria Chan, Christopher J. Patterson, Andrew Keezer, Kirsten Meid, Toni Dubeau, Guang Yang, Zachary R. Hunter, Steven P. Treon, Jorge J. Castillo	0
15	Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia 2018 ·Blood ·Amanda Kofides, Maria Demos, Nickolas Tsakmaklis, Lian Xu, Xia Liu, Christopher J. Patterson, Maria Luisa Guerrera, Manit Munshi, Guang Yang, Jiaji G. Chen, Cristina Jiménez, Gloria Chan, Joshua Gustine, Jorge J. Castillo, Steven P. Treon, Zachary R. Hunter	2
16	Mutated MYD88 Homozygosity Is Increased in Previously Treated Patients with Waldenstrom's Macroglobulinemia, and Associates with CXCR4 Mutation Status and Ibrutinib Exposure 2017 ·Blood ·Nickolas Tsakmaklis, Lian Xu, Robert Manning, Guang Yang, Xia Liu, (unknown), Maria Demos, Amanda Kofides, Gloria Chan, Maria Luisa Guerrera, Christopher J. Patterson, Jorge J. Castillo, Steven P. Treon, Zachary R. Hunter	2
17	MYD88 Mutation Status Impacts Overall Survival and Risk of Histological Transformation in Waldenstrom's Macroglobulinemia 2017 ·Blood ·Steven P. Treon, Zachary R. Hunter, Joshua Gustine, Kirsten Meid, Lian Xu, Xia Liu, Guang Yang, Manit Munshi, Robert Manning, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, (unknown), Gloria Chan, Christopher J. Patterson, Toni Dubeau, Patricia Severns, Jorge J. Castillo	1
18	Mutated MYD88 Activates the BCR Component SYK and Provides a Rationale Therapeutic Target in Waldenstrom's Macroglobulinemia 2017 ·Blood ·Manit Munshi, Xia Liu, (unknown), Lian Xu, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, Gloria Chan, Zachary R. Hunter, Christopher J. Patterson, Joshua Gustine, Jorge J. Castillo, Steven P. Treon, Guang Yang	1
19	The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia 2014 ·Leukemia ·Yang Cao, Zachary R. Hunter, Xingguang Liu, Lian Xu, Guang Yang, (unknown), Christopher J. Patterson, Nickolas Tsakmaklis, Sandra Kanan, Scott J. Rodig, Jorge J. Castillo, Steven P. Treon	154
20	CXCR4 WHIM‐like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88^L265P‐directed survival signalling in Waldenström macroglobulinaemia cells 2014 ·British Journal of Haematology ·Yang Cao, Zachary R. Hunter, Xia Liu, Lian Xu, Guang Yang, Jie Chen, Nickolas Tsakmaklis, Sandra Kanan, Jorge J. Castillo, Steven P. Treon	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact